Introduction - 09/08/11
Doi : 10.1016/j.jaad.2005.10.050
Correspondence to: Mark Lebwohl, MD, Department of Dermatology, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029.New York, New York, and Thousand Oaks, California
| Supported by Amgen Inc and Wyeth Research. Conflicts of interest: Dr Lebwohl received an honorarium for this manuscript. He is a consultant (or has pending consulting agreements) for Abbott, Amgen, Biogen, Centocor, Genentech, Novartis, and Warner Chilcott. In the last 12 months, Dr Lebwohl also has served as a speaker for Abbott, Amgen, Biogen, Connetics, Fujisawa, Galderma, and Genentech. In the past 12 months, members of Dr Lebwohl’s department have served as investigators for Abbott, Allergan, Amgen, Biogen, Centocor, Connetics, Fujisawa, Genentech, and Novartis. Dr Thompson is an employee of and has been granted stock options in Amgen, Inc. Reprints not available from the authors. |
© 2006
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 54 - N° 3S2
P. S65-S66 - mars 2006 Retour au numéro
Article précédent
- Table of contents
- Innate and adaptive immunity and the pathophysiology of psoriasis
- Anthony A. Gaspari
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?